All In Biotech

NDA 212306 · Karyopharm Theraps

Xpovio

Selinexor · Oral · Nuclear Export Inhibitor

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Jul 3, 2019

Approved uses

4

Original approval plus efficacy supplements

Registered trials

194

19 Phase 3, 40 recruiting

FAERS reports

8,763

4,819 serious, 1,486 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 12, 2026.

XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). 1.1 Multiple Myeloma XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Mechanism: In nonclinical studies, selinexor reversibly inhibits nuclear export of tumor suppressor proteins (TSPs), growth regulators, and mRNAs of oncogenic proteins by blocking exportin 1 (XPO1). XPO1 inhibition by selinexor leads to accumulation of TSPs in the nucleus and reductions in several oncoproteins, such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells. Selinexor demonstrated pro-apoptotic activity in vitro in multiple myeloma cells and showed anti-tumor activity in murine xenograft models of multiple myeloma. The combination of selinexor and dexamethasone or...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

6 products under this application
  • XPOVIO · SELINEXOR 10MG · TABLET, ORAL · Prescription
  • XPOVIO · SELINEXOR 50MG · TABLET, ORAL · Prescription
  • XPOVIO · SELINEXOR 20MG · TABLET, ORAL · Prescription
  • XPOVIO · SELINEXOR 80MG · TABLET, ORAL · Prescription
  • XPOVIO · SELINEXOR 60MG · TABLET, ORAL · Prescription
  • XPOVIO · SELINEXOR 40MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Selinexor" as an intervention, any sponsor and status, largest first.

All 194 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea2,648
  • fatigue2,018
  • decreased appetite1,406
  • diarrhoea1,351
  • plasma cell myeloma1,199
  • vomiting956
  • asthenia880
  • death866
  • thrombocytopenia768
  • platelet count decreased698
  • weight decreased654
  • off label use545

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20155
20166
201712
201814
2019606
20201,378
20211,439
20221,235
20231,222
20241,167
20251,051
2026628

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xpovio (Selinexor)

2024 spending

$98.2M

Beneficiaries

1,103

3,428 claims

Per beneficiary

$89,046

$6,013.16 per unit

View as table
YearSpending
2020$48,683,550
2021$69,551,732
2022$86,816,591
2023$85,562,246
2024$98,217,997

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 91 on PubMed

Sponsor: Karyopharm Theraps

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.